Michelle Ferguson

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells

Aparajitha Vaidyanathan, Lynne Sawers, Anne‐Louise Gannon et al. · British Journal of Cancer · 2016 · 354 citations · Full text

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell et al. · The Lancet Oncology · 2018 · 290 citations · Full text

Surgical Oncology, Gynecological Surgery, Individual Patient Data +10

Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>

Barbara A. Spruce, Lorna Campbell, N. McTavish et al. · Cancer Research · 2004 · 165 citations

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

Andre Esteva, Jean Feng, Douwe van der Wal et al. · npj Digital Medicine · 2022 · 165 citations · Full text

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Gbrca M, Medicine, Gynecology +6